Two of the vaccines we have for COVID-19 have the distinction of being the first mRNA vaccines to see widespread use in ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Dr. Robert Malone — a member of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Hongene Biotech receives grant from Gates Foundation to develop and expand global access to mRNA vaccine raw materials: Singapore Saturday, January 24, 2026, 11:00 Hrs [IST] Honge ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...